NO964053L - Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene - Google Patents

Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene

Info

Publication number
NO964053L
NO964053L NO964053A NO964053A NO964053L NO 964053 L NO964053 L NO 964053L NO 964053 A NO964053 A NO 964053A NO 964053 A NO964053 A NO 964053A NO 964053 L NO964053 L NO 964053L
Authority
NO
Norway
Prior art keywords
atoms
compounds
substituents
alkyl
independently represent
Prior art date
Application number
NO964053A
Other languages
English (en)
Other versions
NO964053D0 (no
Inventor
Andreas Weichert
Joachim Brendel
Heinz-Werner Kleemann
Hans Jochen Lang
Jan-Robert Schwark
Wolfgang Scholz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO964053D0 publication Critical patent/NO964053D0/no
Publication of NO964053L publication Critical patent/NO964053L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det er beskrevet forbindelser med formel (I) hvori substituentene kan ha nere betydninger og blant annet bety følgende, minst en av substituentene R(l), R(2) og R(3) kan bety R(6)-C(0H)2-: hvor P(6) betyr perfluoralkyl med 1, 2 eller 3 C-atomer, scB er rettkjedet eller forgrenet; og de øvrige substituentene R(l), R(2) og R(3) betyr uavhengig av hverandre hydrogen, OH, F, Cl, Br, J, alkyl med 1, 2. 3, 4, 5 eller 6 C-atomer, cykloalkyl med 3, 4. 5 eller 6 C-atomer, alkoksy med 1, 2, 3 eller 4 C-atotner eller fenoksy, som er usubstituert eller substituert med 1-3 substltuenter valgt fra gruppen bestående av F, Cl, metyl og metoksy; R(4) og R(5) betyr uavhengig av hverandre hydrogen, alkyl med 1, 2 eller 3 C-atcmer, F. Cl, Br, J, CN, 0R(13), NR(14)R(15). -(CH2)n-(CF2)o-CF3; R(13), R(14) og R(15) betyr uavhengig av hverandre hydrogen eller alkyl med l! 2. 3 eller 4 C-atooer; n betyr 0 eller 1; o betyr 0, 1 eller 2; samt deres fanitologisk akseptable salter. Forbindelsene oppnås ved omsetning av en forbindelse (II) R(1) I med guanldln, hvori R(l) til R(5) har den angitte betydningen og L stårfor en lett nukleofllt, substituerbar avspaltbar gruppe. R(4) 0 Forbindelse (I) er fremragende hjertekretsløps-terapeutiske midler.
NO964053A 1995-09-27 1996-09-26 Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene NO964053L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95115240A EP0765867A1 (de) 1995-09-27 1995-09-27 Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament

Publications (2)

Publication Number Publication Date
NO964053D0 NO964053D0 (no) 1996-09-26
NO964053L true NO964053L (no) 1997-04-01

Family

ID=8219659

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964053A NO964053L (no) 1995-09-27 1996-09-26 Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene

Country Status (20)

Country Link
US (1) US5747541A (no)
EP (1) EP0765867A1 (no)
JP (1) JPH09124584A (no)
KR (1) KR970015568A (no)
AR (1) AR004004A1 (no)
AU (1) AU6584696A (no)
BR (1) BR9603911A (no)
CA (1) CA2186580A1 (no)
CZ (1) CZ280896A3 (no)
HR (1) HRP960430A2 (no)
HU (1) HUP9602640A3 (no)
IL (1) IL119293A0 (no)
MX (1) MX9604338A (no)
NO (1) NO964053L (no)
NZ (1) NZ299445A (no)
PL (1) PL315050A1 (no)
SK (1) SK122596A3 (no)
TR (1) TR199600753A1 (no)
TW (1) TW339327B (no)
ZA (1) ZA968091B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
EP1289961A1 (en) 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
CA2447765C (en) 2001-05-24 2011-01-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
EP1485093B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7253218B2 (en) * 2004-03-01 2007-08-07 H.B. Fuller Company Sound damping compositions and methods for applying and baking same onto substrates
WO2007136636A1 (en) * 2006-05-17 2007-11-29 Childrens Hospital Los Angeles Research Institute Drug combinations to treat hyperproliferative disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DK0556674T3 (da) * 1992-02-15 1996-10-14 Hoechst Ag 3,5-Substituerede benzoylguanidiner med antiarytmisk virkning og inhiberende virkning på celleproliferation
EP0556673B1 (de) * 1992-02-15 1997-09-17 Hoechst Aktiengesellschaft Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0589336B1 (de) * 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
TW250477B (no) * 1992-12-15 1995-07-01 Hoechst Ag
TW250479B (no) * 1992-12-15 1995-07-01 Hoechst Ag
DE59306029D1 (de) * 1992-12-16 1997-05-07 Hoechst Ag 3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0604852A1 (de) * 1992-12-28 1994-07-06 Hoechst Aktiengesellschaft 2,4-Substituierte 5-(N-substituierte-Sulfamoyl)-Benzoylguanidine, als Antiarrythmika, Inhibitoren der Proliferationen von Zellen, und Inhibitoren des Natrium-Protonen-Antiporters
DK0612723T3 (da) * 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5372607A (en) * 1993-06-23 1994-12-13 Medtronic, Inc. Method and apparatus for monitoring pacemaker intervals
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4327176C1 (de) * 1993-08-13 1995-01-26 Metallgesellschaft Ag Röhrenofen für die Erzeugung kohlenmonoxidhaltiger Gasgemische
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
DE4402057A1 (de) * 1994-01-25 1995-08-03 Hoechst Ag Perfluoralkylgruppen tragende phenyl-substituierte Alkylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
TW415937B (en) * 1994-01-25 2000-12-21 Hoechst Ag Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421536A1 (de) * 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4422685A1 (de) * 1994-06-29 1996-01-04 Hoechst Ag Ortho-amino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4441880A1 (de) * 1994-11-24 1996-05-30 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0723956B1 (de) * 1995-01-30 1999-10-13 Hoechst Aktiengesellschaft Basisch-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
CA2186580A1 (en) 1997-03-28
HU9602640D0 (en) 1996-11-28
NO964053D0 (no) 1996-09-26
HUP9602640A3 (en) 1997-11-28
BR9603911A (pt) 1998-06-09
AR004004A1 (es) 1998-09-30
US5747541A (en) 1998-05-05
CZ280896A3 (en) 1997-06-11
HUP9602640A2 (en) 1997-05-28
KR970015568A (ko) 1997-04-28
SK122596A3 (en) 1997-05-07
MX9604338A (es) 1997-03-29
NZ299445A (en) 1997-11-24
AU6584696A (en) 1997-04-10
JPH09124584A (ja) 1997-05-13
ZA968091B (en) 1997-03-27
HRP960430A2 (en) 1998-02-28
PL315050A1 (en) 1997-04-01
IL119293A0 (en) 1996-12-05
TR199600753A1 (tr) 1997-04-22
TW339327B (en) 1998-09-01
EP0765867A1 (de) 1997-04-02

Similar Documents

Publication Publication Date Title
NO964053L (no) Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene
DK0676398T3 (da) Heterocykliske forbindelser, som har antidiabetisk aktivitet, deres fremstilling og deres anvendelse
MY129970A (en) Hypolipidaemic compounds
DK328579A (da) Alkylderivater af c-076 forbindelser og fremgangsmaade til fremstilling deraf
KR950005812A (ko) 피리미딘 및 피리딘 유도체, 그의 제조방법 및 용도
HUT59404A (en) Heterocyclic compounds
NO940550L (no)
MX9804457A (es) Inhibidores de las metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y metodos y compuestos intermedios utiles para su preparacion.
MX9201577A (es) Analogos de trifosfato de adenina.
NO20004485L (no) Sykloalkenderivater, deres fremstilling og anvendelse
DE69530706D1 (de) Huperzin-derivate, ihre herstellung und ihre verwendung
NO943510D0 (no) Azolforbindelser, deres fremstilling og anvendelse
TW208014B (no)
DK331781A (da) Arylamin-derivater samt deres fremstilling og anvendelse som mikrobicider
GB906183A (en) New esters of n-substituted carbamic acids
IE791490L (en) Phenyl-alkanoic acids
MX9602841A (es) Benzoilguanidinas sustituidas con fluoroalquilo en la posicion 4, un procedimiento para su preparacion, su utilizacion como medicamento o agente diagnostico, asi como un medicamento que las contiene.
NO960307L (no) Fremgangsmåte ved fremstilling av substituerte 4,6-diamino-5-cyanopyrimidiner
DE3472104D1 (en) N-substituted ûbis(hydroxymethyl)-methyl¨-isoquinoline derivatives, process for preparing them and pharmaceutical compositions containing them
CA2419279A1 (en) Prodrugs to nmda receptor ligands
NO930739L (no) Substituerte fenylkinazolinderivater
WO2003061552A3 (en) Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
GB1598630A (en) N-cyano-n'-alkynyl-n''-(2-mercaptoethyl)-guanidines
US4083868A (en) 2-(α-Amidobenzyl)-5-alkylresorcinols